Month: June 2026

Introduction and Objective: Accurate control population-based thresholds for Islet autoantibodies positivity are essential to diagnosed and predict type 1 diabetes (T1D). Most positivity thresholds come from European populations, and it remains unclear whether these thresholds differ across ancestries within the same country.Methods: We analyzed GADA, IA-2A and ZnT8A in 1543 diabetes-free adults (595 -European, 474 […]

Introduction and Objective: Recent evidence suggests that extra-pancreatic tissues, including the stomach, may also express insulin. The aim of this study was to investigate whether the human stomach expresses insulin and key β-cell-associated transcriptional markers, and to characterize the cellular and spatial context of such expression.Methods: Gastric biopsies were obtained from 15 human subjects undergoing […]

Introduction and Objective: As diabetes care increasingly resides in primary care, patients with severe medical and psychosocial complexity remain challenging to manage. The Care Plus clinic is a high-intensity, multidisciplinary primary care program for high-need, high-cost (HNHC) patients that was expanded to include individuals with poorly controlled diabetes (HbA1C >10%). This study evaluated the impact […]

Introduction and Objective: Heart failure (HF) is a major global cause of mortality, and its prevalence is increasing with rising obesity rates, particularly in HFpEF. Urocortin-2 (UCN2) exerts beneficial cardiovascular effects, including vasodilation and improved cardiac function in HF. HM17321 is a CRFR2-selective UCN2 analog currently in phase 1 clinical development as an anti-obesity therapy […]

Introduction and Objective: Insulin resistance is an underlying pathophysiology of type 2 diabetes inadequately addressed by current treatment options. The new mitochondrially directed insulin sensitizer CIS-0602K was designed to maintain the pharmacology of the first-generation pioglitazone without direct PPARg side effects but which still works independent of weight loss and even when there is a […]

Introduction and Objective: Heart failure (HF) is a frequently unrecognized complication in people living with diabetes. Clinical practice guidelines recommend screening for HF using natriuretic peptide testing. We examined the performance of the AHA PREVENT risk model to detect unrecognized HF in a randomized trial of NT-proBNP-based screening in patients with diabetes and risk factors […]

Introduction and Objective: Black and African American (BAA) women have a high burden of type 2 diabetes (T2D) and diabetes distress (DD). We tested the efficacy of a culturally-tailored Diabetes Tune-Up Group intervention delivered in-person or by synchronous video call (VC) to BAA women with DD and T2D.Methods: 63 BAA women were enrolled in a […]

Introduction and Objective: Cardiovascular (CV) risk increases with age in T1D, but the role of adiposity in this progression is unclear. We used mediation analysis to determine if rising BMI explains the age-related increase in CV risk.Methods: We analyzed 1,266 patients living with T1D (52.1% male). CV risk was defined as a composite of hypertension, […]

Introduction and Objective: Individuals with type 2 diabetes (T2D) are 1.5-2 times more likely to develop Alzheimer’s disease and related dementias (ADRD) than those without. Despite evidence that midlife cardiovascular risk factors increase later-life cognitive decline, limited data exist on ADRD knowledge and misconceptions among middle-aged adults with T2D. Guided by the Science of Behavioral […]

Introduction and Objective: GLP-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity but frequent injections may limit adherence. PT403 is a long-acting semaglutide formulation based on biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres designed for once-monthly administration. This study evaluated the pharmacological efficacy, safety, and tolerability of PT403 and explored its translational development potential as […]